Ritu Baral, an analyst from TD Cowen, maintained the Hold rating on Sarepta Therapeutics. The associated price target remains the same with $17.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ritu Baral has given her Hold rating due to a combination of factors impacting Sarepta Therapeutics. The company’s recent financial performance showed a significant net loss of $180 million in the third quarter, with a loss per share of $1.80, which was below market expectations. Despite this, the revenue from Elevidys and PMO exceeded consensus estimates, indicating strong sales performance.
However, there are concerns about future revenue projections, as Sarepta guided to flat or slightly decreased revenue for Elevidys in the fourth quarter due to seasonal factors and other disruptions. Additionally, the company’s research and development and SG&A expenses remain high, with guidance for fiscal year 2025 set at approximately $1.9 billion. These mixed signals, along with the challenges faced by Amondys and Vyondys in their confirmatory trials, contribute to the Hold rating.
In another report released today, Morgan Stanley also maintained a Hold rating on the stock with a $20.00 price target.